Pelvic Floor Repair in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Women with symptomatic POP-Q Stage II, III, or IV pelvic organ prolapse (anterior cystocele, posterior rectocele/enterocele, or apical uterine/vault prolapse) who have failed conservative management (minimum 3–6 months of supervised PFMT and/or pessary use)

• Patients with concomitant stress urinary incontinence requiring combined mid-urethral sling (TVT/TOT) and prolapse repair in a single operative setting

• Women with obstructive defaecation syndrome secondary to rectocele or sigmoidocele confirmed on dynamic MRI defaecography

• Patients with symptomatic vaginal vault prolapse following prior hysterectomy

• Sexually active patients with bothersome vaginal bulge, pressure, or coital difficulty scoring above threshold on validated outcome measures (PFDI-20, PFIQ-7, PISQ-12)

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Pelvic floor MRI (dynamic/functional MRI defaecography for posterior compartment assessment)

• Full urodynamic study (UDS) including cystometry, pressure-flow study, and urethral pressure profilometry to detect occult stress incontinence and detrusor overactivity

• Transvaginal/transperineal pelvic floor ultrasound (levator ani integrity, mesh assessment in re-do cases)

• POP-Q clinical examination by urogynaecologist with prolapse staging at maximum Valsalva

• Blood panel: FBC, coagulation profile (PT/INR/aPTT), renal and hepatic function, HbA1c (if diabetic), serum albumin (nutritional status for wound healing)

• 12-lead ECG and anaesthetic fitness assessment (ASA classification)

• Urine culture and sensitivity (mandatory; surgery deferred if active UTI present)

• Cervical smear (Pap test) and endometrial assessment (if uterine preservation planned)

• CONTRAINDICATIONS (ABSOLUTE):

• Active pelvic or systemic infection

• Uncontrolled coagulopathy or anticoagulation that cannot be safely bridged

• Undiagnosed pelvic or uterine malignancy

• Current pregnancy

• CONTRAINDICATIONS (RELATIVE / REQUIRES MULTIDISCIPLINARY REVIEW):

• Severe cardiopulmonary disease (ASA IV) precluding general or regional anaesthesia

• Active smoking (increases mesh erosion risk; cessation ≥8 weeks recommended pre-operatively)

• Morbid obesity (BMI >40; bariatric surgery or significant weight loss recommended first)

• Significant vaginal atrophy (pre-operative topical oestrogen therapy for 6–12 weeks recommended)

• Prior pelvic radiation therapy (significantly increases complication risk)

• Desire for future pregnancy (surgery typically deferred until family is complete)

COMPARTMENT-SPECIFIC NATIVE-TISSUE REPAIRS (First-Line Surgical Options):

1. Anterior Colporrhaphy (Cystocele Repair): Midline fascial plication of the pubocervical fascia addresses anterior vaginal wall descent. Anatomical success rates of 70–80% at 5 years; preferred in patients with mild-moderate cystocele and adequate fascial tissue. Paravaginal repair (laparoscopic or open) corrects lateral detachment defects of the pubocervical fascia from the arcus tendineus fascia pelvis (ATFP).

2. Posterior Colporrhaphy with Perineorrhaphy: Site-specific rectovaginal fascial repair or midline plication corrects rectocele and perineal body deficiency. Dynamic defaecography guides extent of repair. Anatomical success approximately 75–85%.

3. Sacrospinous Ligament Fixation (SSLF): Vaginal-access apical suspension anchoring the vaginal vault or cervix to the sacrospinous ligament unilaterally (Richter procedure) or bilaterally. Appropriate for vault prolapse or uterine prolapse with uterine sparing (hysteropexy variant). Success rates 80–90% at 2 years; risk of de novo posterior wall prolapse due to posterior vault angulation.

4. Uterosacral Ligament Suspension (USLS / McCall Culdoplasty): High vaginal or laparoscopic ligation of the uterosacral ligaments at the level of the ischial spine provides superior apical support. Ureteroscopy or cystoscopy mandatory intra-operatively to confirm ureteric patency (ureteric kinking risk ~5–11%).

MESH-AUGMENTED REPAIRS (Selected Cases, Regulatory-Compliant):

5. Abdominal Sacrocolpopexy (Open or Laparoscopic): Polypropylene Y-mesh fixation from the vaginal apex (and anterior/posterior walls) to the sacral promontory via the presacral space. Gold standard for vault prolapse with >90% objective cure at 5–7 years. Laparoscopic approach reduces blood loss and hospital stay compared to open.

6. Robotic-Assisted Sacrocolpopexy (RASC): Performed on da Vinci Surgical System platforms available at top-tier centres in India (Apollo, Fortis, Manipal) and UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai). RASC offers 3D magnification, EndoWrist articulation in the deep pelvis, and tremor filtration—critical advantages in the narrow presacral space. Mesh placement is more precise, and suturing at the sacral promontory and vaginal cuff is ergonomically superior to straight-stick laparoscopy. Published RCT data (CARE trial, OPTIMAL trial) confirm non-inferiority to open sacrocolpopexy with significantly reduced recovery time. Anatomical success at 2 years: 91–95%.

COMBINED PROCEDURES (Routine in High-Volume Centres):

7. Mid-Urethral Sling (TVT / TOT / Single-Incision Mini-Sling): Simultaneous placement at the time of prolapse repair for coexistent or unmasked stress urinary incontinence. Tension-free vaginal tape (TVT, retropubic) or transobturator tape (TOT) are performed concurrently under urodynamic guidance.

8. Sacrohysteropexy (Uterine-Preserving Apical Repair): Increasingly preferred in younger patients or those declining hysterectomy. Laparoscopic or robotic mesh attachment from the cervix/uterine isthmus to the sacral promontory preserves fertility (with caveats) and hormonal uterine function. Comparable apical success to sacrocolpopexy in 5-year data.

9. Obliterative Procedures (Colpocleisis – LeFort Partial / Total): Indicated exclusively for elderly, medically frail patients not desiring future sexual intercourse. Colpocleisis closes the vaginal lumen, eliminating prolapse with very high success (~95%) and minimal operative morbidity. Concurrent anti-incontinence procedure is routinely added.

ADJUNCT TECHNOLOGIES:

• Intraoperative cystoscopy (mandatory after all apical repairs and mid-urethral slings)

• Fluorescence-guided ureteral stenting in complex re-do cases

• Pelvic floor neuromodulation (sacral neuromodulation / Interstim) for refractory detrusor overactivity identified on pre-operative UDS

• Post-operative pelvic floor physiotherapy and biofeedback (standard protocol at accredited centres)

PRE-OPERATIVE PHASE (Weeks 1–4 before surgery):

Step 1 – GAF Healthcare Initial Consultation: Upload medical records, imaging, and urodynamic reports to the GAF patient portal. A dedicated medical coordinator reviews your case within 24 hours and connects you with a board-certified urogynaecologist at your chosen destination (India or UAE) for a telemedicine second opinion.

Step 2 – Treatment Planning & Cost Estimate: The urogynaecology team reviews POP-Q staging, UDS findings, and imaging. A written surgical plan (e.g., robotic sacrocolpopexy + TVT sling, or posterior colporrhaphy + USLS) and itemised cost estimate are issued within 48 hours.

Step 3 – Pre-Travel Optimisation (Weeks 1–3): Topical vaginal oestrogen commenced if atrophy is present (6–12 weeks ideally; minimum 4 weeks). Smoking cessation confirmed. Anticoagulation bridging plan established with cardiologist if applicable. PFMT sessions commenced or continued.

Step 4 – Arrival & Pre-Admission Workup (Day 1–2 in-country): Airport transfer arranged by GAF Healthcare. Pre-admission blood panel, urine culture, ECG, and anaesthetic assessment completed at the hospital. Dynamic pelvic MRI or UDS performed if not recently completed.

Step 5 – Surgical Day (Day 3): General or spinal anaesthesia administered. Operative time: 60–180 minutes depending on procedure complexity. Intraoperative cystoscopy performed prior to closure. Patient recovered in PACU (post-anaesthesia care unit) then transferred to private room.

POST-OPERATIVE HOSPITAL PHASE (Days 3–7):

Step 6 – Immediate Post-Op (24–48 hours): Urinary catheter in situ (typically removed at 24–48 hours post-op; trial of void performed). Early ambulation at 6–12 hours post-operatively to reduce DVT risk. VTE prophylaxis: LMWH (low molecular weight heparin, e.g., enoxaparin) and TED stockings commenced. Intravenous antibiotics transitioned to oral. Pain managed with multimodal analgesia (NSAIDs + paracetamol; opioids avoided or minimised).

Step 7 – Hospital Discharge (Day 3–5 post-surgery): Confirmed voiding efficiency (post-void residual <100 mL on bladder scan). Bowel function confirmed (dietary fibre and osmotic laxatives prescribed to prevent straining). Wound review and discharge summary issued. Stool softeners prescribed for minimum 6 weeks.

POST-OPERATIVE RECOVERY PHASE (Weeks 1–6 in-country):

Step 8 – Week 1–2 (Hotel / Serviced Apartment Recovery): Rest and gentle ambulation. No lifting >2 kg. Pelvic rest (no vaginal intercourse, tampons, or pelvic examinations). Daily wound care. GAF coordinator conducts daily check-in calls.

Step 9 – Week 2–3 (Outpatient Follow-Up): Surgical review at treating hospital. Wound check, catheter-free voiding assessment, and pelvic examination. Any de novo symptoms (urinary urgency, constipation, pelvic pressure) assessed and managed.

Step 10 – Fit-to-Fly Assessment (Week 4–6): Attending urogynaecologist issues formal medical fitness-to-fly letter. Short-haul flights (under 4 hours): cleared at 3–4 weeks for uncomplicated laparoscopic/robotic procedures. Long-haul international flights (over 6 hours): cleared at 5–6 weeks. Compression stockings, in-flight ambulation, and continued LMWH (if applicable) instructions provided.

STEP 11 – Long-Term Recovery Milestones:

• Return to desk/sedentary work: 2–3 weeks

• Return to light walking/low-impact activity: 4–6 weeks

• Return to driving: 4–6 weeks (when off opioids and able to perform emergency stop)

• Return to sexual intercourse: 8–12 weeks

• Return to heavy lifting/strenuous exercise: 12 weeks minimum

• 3-month post-operative POP-Q re-staging and UDS: standard follow-up protocol

• 12-month objective success assessment (POP-Q, validated questionnaires PFDI-20/PFIQ-7): gold-standard outcome benchmark